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A B S T R A C T   
The PI3K/AKT pathway is an intracellular signaling pathway with an indispensable impact on cell cycle control. 
This pathway is functionally related with cell proliferation, cell survival, metabolism, and quiescence. The crucial 
role of this pathway in the development of cancer has offered this pathway as a target of novel anti-cancer 
treatments. Recent researches have demonstrated the role of microRNAs (miRNAs) and long noncoding RNAs 
(lncRNAs) in controlling the PI3K/AKT pathway. Some miRNAs such as miR-155-5p, miR-328-3p, miR-125b-5p, 
miR-126, miR-331-3p and miR-16 inactivate this pathway, while miR-182, miR-106a, miR-193, miR-214, miR- 
106b, miR-93, miR-21 and miR-103/107 enhance activity of this pathway. Expression levels of PI3K/AKT- 
associated miRNAs could be used to envisage the survival of cancer patients. Numerous lncRNAs such as 
GAS5, FER1L4, LINC00628, PICART1, LOC101928316, ADAMTS9-AS2, SLC25A5-AS1, MEG3, AB073614 and 
SNHG6 interplay with this pathway. Identification of the impact of miRNAs and lncRNAs in the control of the 
activity of PI3K/AKT pathway would enhance the efficacy of targeted therapies against this pathway. Moreover, 
each of the mentioned miRNAs and lncRNAs could be used as a putative therapeutic candidate for the interfering 
with the carcinogenesis. In the current study, we review the role of miRNAs and lncRNAs in controlling the PI3K/ 
AKT pathway and their contribution to carcinogenesis.   
1. Introduction 
The PI3K/AKT pathway is an intracellular signaling cascade with an 
indispensable effect on cell cycle. This pathway is functionally associ-
ated with cell proliferation, quiescence, and cancer [1]. PI3K can be 
triggered by receptor tyrosine kinases, G protein-coupled receptors, and 
small-GTPases. Subsequently, PI3K can facilitate the conversion of PIP2 
to PIP3 which leads to the recruitment of PH-domain-containing mem-
brane proteins including AKT and mTORC2 [2]. When PI3K is activated, 
it initiates a number of reactions that finally phosphorylates and acti-
vates AKT [1]. Activation of AKT leads to several effects including CREB 
activation [3], suppression of p27 activity [4], modulation of FOXO 
subcellular localization, and activation of mTOR [4]. Several factors 
such as EGF [5], shh [3], IGF-1 [3], insulin [4], and CaM [6] have been 
identified as activators of the PI3K/AKT pathway. On the other hand, 
PTEN [7], GSK3B [3], HB9 [5], and SHIP1/2 and INPP4B [2] are known 
as inhibitors of this pathway. The role of PI3K in carcinogenesis has been 
initially discovered more than three decades ago through the observed 
association between this protein and the transforming function of viral 
oncogenes [8]. Several years later, independent studies revealed muta-
tions in PIK3R1 [9] and PIK3CA [10] genes in numerous kinds of solid 
tumors, further highlighting the association between PI3K and carci-
nogenesis. Subsequently, PIK3CA was recognized as one of the most 
commonly activated oncogenes in diverse malignancies [11,12]. More-
over, up-regulation of the activity of the PI3K/AKT pathway has been 
demonstrated in many cancers, leading to impediment of apoptosis and 
augmentation of cell proliferation [2]. Such a process is exerted via 
modulation of numerous main nodes of the pathway [13]. Fig. 1depicts 
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an overview of PI3K/AKT signaling cascade which plays a significant 
role in the regulation of various cellular survival pathways like JNK, 
ERK, NFκB, and is involved in the cardiovascular homeostasis, glucose 
metabolism as well as synaptic signaling. 
2. FmiRNAs and PI3K/AKT pathway 
Numerous miRNAs are connected with PI3K/AKT pathway and the 
pathogenesis of human cancers. Both up-regulated and down-regulated 
miRNAs in cancers are implicated in this process. 
3. Down-regulated PI3K/AKT-associated miRNAs in cancers 
Expression of miR-155-5p has been down-regulated in both blood 
and tumor sections of patients with Wilms’ tumor (WT) who did not get 
chemotherapy prior to surgery but was increased in tumor samples of 
those who had received chemotherapy prior to surgery. Moreover, 
expression levels of IGF2, PI3K, AKT, and mTOR have been increased in 
WT tissues. Further studies indicated that this miRNA acts as a tumor 
suppressor in this type of malignancy via inhibiting the PI3K/AKT/ 
mTOR cascade. This function is mediated through the inhibition of IGF2 
by miR-155-5p [14]. miR-328-3p has been down-regulated in bladder 
cancer tissues in association with the poor prognosis of patients. 
Mechanistically, this miRNA blocks cell proliferation, migratory apti-
tude, and invasiveness via binding with 3’ untranslated region (UTR) of 
ITGA5, thus suppressing epithelial-mesenchymal transition (EMT) and 
inactivating PI3K/AKT signaling in bladder cancer tissues [15]. Other 
investigations in bladder cancer samples revealed down-regulation of 
miR-125b-5p in cancer tissues and cell lines. Notably, down-regulation 
of miR-125b-5p has been linked with poor patients’ survival, a higher 
Fig. 1. A schematic diagram of the PI3K/AKT/mTOR pathway. AKT, or alternatively named as protein kinase B (PKB) is a serine/threonine kinase with an 
effective regulatory role in various cellular survival pathways, principally as a suppressor of apoptosis as well as cellular processes of oncogenesis, angiogenesis, 
autophagy and metabolism. Dysregulation of the PI3K/AKT pathway is involved in various human diseases namely neoplasms, diabetes, cardiovascular disorders, 
and neurological disorders. Binding of a growth factor (e.g., EGF, HGF, PDGF, and VEGF) to RTK could activate this receptor tyrosine kinase. PI3K is composed of two 
subunits namely p85 and p110. PI3K could bind to IRS-1, RTK, or GPCR and trigger the enzymatic function of the p110 subunit, which then synthesizes PIP3 in the 
membrane. The accessibility of PIP3 at the plasma membrane could be controlled by the contrary functions of PI3K, that phosphorylates PIP2 to PIP3, and PTEN, that 
dephosphorylates PIP3 and inhibits recruitment of AKT. Subsequently, AKT is recruited to the membrane. Activation of AKT1 could partake in the downstream 
regulation of protein complexes mTORC1 and mTORC2 that could in turn trigger gene transcription and elevate cell growth and cell survival. The activated AKT 
kinase could phosphorylate different substrates including PRAS40 that is subsequently inactivated and releases mTORC1. Furthermore, TSC2 is suppressed, while the 
downstream GTPase Rheb remains GTP-bound and thereby could regulate mTORC1. Activation of mTORC1 complex could alternatively regulates translation ma-
chinery proteins via 4E-BP1 or S6K-1 phosphorylation. AKT signaling have a remarkable role in various human cancers which can pave the way for anti-cancer 
therapeutics. Numerous non-coding RNAs (ncRNAs) have been confirmed to alter the activity of the PI3K/AKT cascade. We review the effect of microRNAs 
(miRNAs) and long non-coding RNAs (lncRNAs) on PI3K/AKT pathway and their contribution to carcinogenesis. 
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Fig. 2. A diagram of the regulation of PI3K/AKT cascade via miRNAs in various human cancers. Different miRNAs including miR-195, miR-320, miR-425, 
miR-579, miR-766, and miR-1231 can modulate activity of PI3K/AKT pathway and block carcinogenic processes. These miRNAs have a tumor suppressor role 
which can impede cell proliferation, migration, and invasion and activate cell apoptosis by modulating their target genes. These miRNAs by directly targeting IGF1, 
ELF3, Rheb, PDK1, IRS2, and EGFR through the PI3K/AKT pathway can suppress a variety of tumors namely rectal cancer, breast cancer, papillary thyroid carci-
noma, melanoma, and glioblastoma [18–24]. Table 1 summarizes the functional data describing the role of tumor suppressor miRNAs which partake in the regulation 
of PI3K/AKT pathway. 
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Table 1 
The function of tumor suppressor miRNAs in the control of PI3K/AKT pathway in cancer (ANCTs: adjacent non-cancerous tissues).  
Cancer Type microRNA Role of 
microRNA 









87 pairs of WT and ANCTs, 
4 WT and 4 uronephrosis 




IGF2 mTOR miR-155-5p by targeting IGF2 
suppresses cell proliferation, 
migration, and invasion and 









Mouse/human; 28 pairs of 
BCa and ANCTs 
SV-HUC-1, 5637, 
T24, J82 
ITGA5 EMT miR-328-3p by targeting 
ITGA5 could inhibit 
tumorigenesis in BCa via 







52 pairs of BCa and ANCTs T24, RT4, J82, 
5637, SV-HUC-1 
HK2 _ miR-125b-5p by targeting HK2 
could suppress BCa cell 
proliferation and migration 
and induce apoptosis via the 
PI3K/Akt pathway. 
[16] 
BCa miR-126 Tumor 
Suppressor 
_ BLS PIK3R2 _ miR-126 by targeting PIK3R2 
could enhance apoptosis and 
inhibit proliferation, 
migration, and invasion in BCa 









60 pairs of NPC and ANCTs NP69, 5-8F, CNE- 
1 
elf4B  miR-331-3p by targeting elf4B 
impedes proliferation and 
invasion and promote 
apoptosis in NPC cells. 
[17] 
NPC miR-16 Tumor 
Suppressor 
Mouse/human; 16 NPC and 






FGF2 MAPK miR-16 by targeting FGF2 
could inhibit NPC cell 







Mouse/human; 33 RB and 




HDAC9 _ miR‑936 by targeting HDAC9 





RB miR‑448 Tumor 
Suppressor 




ROCK1 _ miR‑448 by targeting ROCK1 









Mouse AMC-HN-8 _ _ miR-145 could inhibit tumor 
growth, invasion, and 
metastasis in LSCC. 
[29] 
LSCC miR-144 Tumor 
Suppressor 
Mouse/human; 24 pairs of 
LSCC and ANCTs 
HEp-2 IRS1 _ miR-144 by targeting IRS1 
could suppress tumor growth 













miR-133b by targeting EGFR 
could suppress cell 
proliferation, migration, and 
invasion in ESCC cells via 




Breast Cancer (BC) miR-1469 Tumor 
Suppressor 
48 pairs of BC and ANCTs, 
48 BC blood samples, and 








miR-1469 by targeting HOXA1 
impedes cell proliferation, 
migration, and invasion and 
enhance apoptosis via PTEN/ 
PI3K/Akt and Wnt/β-catenin 
cascades. 
[32] 
BC miR-204 Tumor 
Suppressor 




PTEN _ miR-204 by targeting PTEN 
could inhibit proliferation and 
metastasis in BC. 
[33] 
BC miR-320 Tumor 
Suppressor 
Mouse/human; 52 pairs of 





ELF3 EMT miR-320 by inhibiting ELF3 
could suppress the progression 













_ miR-361-5p by targeting 
RQCD1 could inhibit 
migration and invasion in 
TNBC cells via EGFR/PI3K/Akt 
pathway. 
[34] 
Glioma (G) miR-1231 Tumor 
Suppressor 
Mouse/human; 24 G and 5 
normal brain tissues/ 
U251, LN229, 
A172, U87, 
U118, H4, NHAs 
EGFR _ miR-1231 by targeting EGFR 
could suppress cell 
[19] 
(continued on next page) 
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Table 1 (continued ) 
Cancer Type microRNA Role of 
microRNA 





CGGA, TCGA, and 
GSE10611 datasets 
proliferation and block cell 
cycle arrest. 
G miR-126 Tumor 
Suppressor 
44 G and 20 normal brain 
tissues 
U87MG, NHA PTEN, 
MDM2 
p53 miR-126 by targeting PTEN 
and MDM2 could suppress 
glioma progression through 
PI3K/Akt and p53 pathways. 
[35] 
G miR-489 Tumor 
Suppressor 
Mouse/human; 60 pairs of 
G and ANCTs 
U87, T98, U251, 
NHA 
SPIN1 _ miR-489 by targeting SPIN1 
could inhibit proliferation, cell 
cycle progression, and induce 






_ A-172, U251, 
293 T 
Rheb, PDK1 mTOR miR-579 by targeting Rheb 
and PDK1could attenuate 
tumor progression in GBM via 






Mouse/human; 61 pairs of 
HCC and ANCTs 
L02, Hep3B, Bel- 
7402, SMMC- 
7721, Huh7, SK- 
HEP-1 
IGF-1R EMT miR-944 by targeting IGF-1R 
could restrict tumor 
progression, metastasis, and 
EMT in HCC cells via the PI3K/ 
Akt pathway. 
[37] 
HCC miR-300 Tumor 
Suppressor 
110 FFPE HCC tissues, 15 







FAK EMT miR-300 by targeting FAK 
affects proliferation, 
migration, and invasion in 
HCC cells via regulating PI3K/ 
Akt and EMT. 
[38] 
HCC miR-623 Tumor 
Suppressor 






miR-623 by targeting XRCC5 
could suppress the progression 
and metastasis of HCC. 
[39] 
HCC miR-1296 Tumor 
Suppressor 
Mouse/human; 126 pairs of 






SRPK1 EMT miR-1296 by targeting SRPK1 
could suppress tumor growth 









29 AML blood samples, 29 





AKT2 _ miR-345-5p by targeting AKT2 
could regulate proliferation 
and cell cycle and facilitate 







51 AML BM samples, 21 




HS-5, 293 T 
Tspan3 _ miR-139-5p by targeting 
Tspan3 inhibits 
leukemogenesis in AML cells 






Mouse/human; 7 BM 
samples and 30 blood 
samples from AML patients, 
2 BM samples and 10 blood 
samples as healthy controls 
THP-1, HL-60, 




miR-183-5p by regulating 
Erbin could enhance the 
proliferation of AML cells 
through induction of RAS/ 
RAF/MEK/ERK and PI3K/Akt/ 
FoxO3a pathways. 
[43] 
Ewing’s Sarcoma miR-185 Tumor 
Suppressor 





miR-185 by targeting E2F6 
could suppress the progression 
of Ewing’s sarcoma via 
inhibiting PI3K/Akt/mTOR 
and Wnt/β-catenin pathways. 
[44] 
Ewing’s Sarcoma miR-30d Tumor 
Suppressor 
_ SK-ES-1 _ MEK/ERK miR-30d could inhibit cell 
progression in Ewing’s 
sarcoma by inhibiting MEK/ 








Mouse/human; 105 EOC 
tissues and 51 normal 
ovarian tissues 
293 T, A2780, 
SKOV-3, OVCAR- 





_ miR-337-3p by targeting 
PIK3CA and PIK3CB could 
suppress the proliferation of 
EOC cells. 
[46] 
OC miR-149 Tumor 
Suppressor 




MSI2 EMT miR-149 by targeting MSI2 
could inhibit OC cell growth 
and metastasis via regulating 






37 EC and 22 normal 
control tissues 
HEC-1A, HEEC _ mTOR miR-101 could reduce cell 
proliferation and invasion and 







Mouse/human; a number of 




GIT1 mTOR miR-149 by targeting GIT1 
could inhibit proliferation and 
enhance apoptosis in cervical 
cancer via the PI3K/Akt 
pathway. 
[49] 
(continued on next page) 
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Table 1 (continued ) 
Cancer Type microRNA Role of 
microRNA 





CC miR-383 Tumor 
Suppressor 
115 pairs of CC and ANCTs HeLa, SiHa, 
CaShi, C4-1 
PARP2 mTOR miR-383 by targeting PARP2 
could inhibit proliferation, 
migration, and invasion in 
cervical cancer cells. 
[50] 
CC miR-99b Tumor 
Suppressor 
132 pairs of CC and ANCTs HeLa, SiHa, 
CaShi, C4-1 
_ mTOR miR-99b could inhibit cell 






Mouse/human; 20 pairs of 
CC and ANCTs 
HeLa, Caski GALNT7, 
EGFR 
_ miR‑125a‑5p by inhibiting 
GALNT7 and EGFR could 
attenuate cell proliferation and 
invasion in CC cells. 
[52] 
CC miR-338 Tumor 
Suppressor 
30 pairs of CC and ANCTs Siha, HeLa, 
C33A, Me180 
ATF2 mTOR miR-338 by targeting ATF2 
could inhibit proliferation and 




CC miR-204 Tumor 
Suppressor 
Mouse/human; 30 pairs of 





EphB2 _ miR-204 by targeting EphB2 
could suppress migration, 
invasion, and metastasis and 








Mouse/human; 49 pairs of 







_ miR-143-3p by targeting 
ITGA6 could suppress tumor 
growth and PLGF-induced 
angiogenesis in GBC via PI3K/ 
Akt/STAT3 signaling. 
[55] 




_ HepG2, L02 DNMT3a _ miR-30a-3p by targeting 
DNMT3a could inhibit the 







Mouse/human; 30 pairs of 
PCa and ANCTs 
LNCap, PC-3, 
DU-145, RPWE-1 
ETS1 mTOR, EMT miR-129 by targeting ETS1 
could inhibit cell proliferation, 






Mouse/human; 180 pairs of 
PCa and ANCTs 
PC-3, LNCaP LAPTM4B _ miR-188-5p by targeting 
LAPTM4B could attenuate cell 
proliferation, migration, and 
invasion and enhance 








patients, 20 pairs of PCa and 
ANCTs, 48 benign prostate 








_ miR-133a-3p by affecting 
several cytokine receptors 
inhibits bone metastasis via 
inactivating the PI3K/Akt axis. 
[59] 
PCa miR-381 Tumor 
Suppressor 




miR-381 by targeting RELN 
could facilitate autophagy and 







Mouse/human; 30 pairs of 
PTC and ANCTs 
K1 AKT3 _ miR-29a by targeting AKT3 
impedes proliferation, 
migration, and invasion and 
induces apoptosis in PTC. 
[61] 
PTC miR-218 Tumor 
Suppressor 
Mouse/human; 21 pairs of 





_ miR-218 by targeting Runx2 
could suppress cell viability, 
invasion, and induce apoptosis 
in PTC via inactivation of 
PTEN /PI3K/Akt pathway. 
[62] 
PTC miR-766 Tumor 
Suppressor 
Mouse/human; 47 pairs of 
PTC and ANCTs 
HT‑ori3, HTH83, 
TPC‑1, BCPAP 
IRS2 _ miR-766 by targeting IRS2 
could inhibit PTC progression, 
migration, and invasion via the 
PI3K/Akt pathway. 
[21] 
Lung Cancer miR-126 Tumor 
Suppressor 
_ SPC‑A1, LLC Snail EMT miR-126 could suppress EMT 
and metastasis. 
[63] 
Lung Cancer miR-600 Tumor 
Suppressor 
_ A549, H1299 METTL3 β-catenin miR-600 by targeting METTL3 
could enhance apoptosis and 








Mouse/human; 54 pairs of 




LMO3 EMT miR-381 by targeting LMO3 
could inhibit LA cell biological 
progression via regulating 









_ NCI-H460, NCI- 
H1975 
PIK3R2 _ miR-30a-5p by reducing 
PIK3R2 could induce cell 
apoptosis and inhibit invasion 






Mouse H1299, SPC-A-1, 
A549, H460, 
H520, MRC-5 
MALAT-1 _ miR-101-3p by targeting 
MALAT-1could inhibit growth 
and metastasis of NSCLC cells. 
[67] 
(continued on next page) 
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Table 1 (continued ) 
Cancer Type microRNA Role of 
microRNA 





NSCLC miR-409 Tumor 
Suppressor 
Mouse/human; 85 pairs of 
NSCLC and ANCTs 
A549, H460 SPIN1 _ miR-409 by targeting blocks 
proliferation, migration, and 
invasion. 
[68] 
NSCLC miR-874 Tumor 
Suppressor 
Mouse/human; 49 pairs of 
NSCLC and ANCTs 
A549, H1299, 
BEAS-2B 
AQP3 EMT miR-874 by inhibiting AQP3 
could attenuate cell 
proliferation, mobility, and 
EMT in NSCLC cells. 
[69] 
NSCLC miR-145 Tumor 
Suppressor 
NSCLC tissues and blood 
samples (n = 6), healthy 
tissues and blood samples as 
control (n = 6) 
A549 EGFR _ miR-145 by targeting EGFR 
could inhibit migration and 







Mouse/human; 80 pairs of 




ELF3 _ miR-320a-3p by targeting 
ELF3 could inhibit cell 
metastasis and invasion in 
NSCLC cells. 
[71] 
NSCLC miR-496 Tumor 
Suppressor 





BDNF _ miR-496 by targeting BDNF 
could suppress tumorigenesis 
via PI3K/Akt signaling 
pathway in NSCLC. 
[72] 
NSCLC miR-223 Tumor 
Suppressor 
6 NSCLC and 6 healthy 
blood samples 
A549 EGFR _ miR-223 by targeting EGFR 
could increase apoptosis and 
suppress tumor progression of 
NSCLC through the PI3K/Akt 
pathway. 
[73] 
Melanoma miR-425 Tumor 
Suppressor 
15 pairs of melanoma 




IGF-1 _ miR-425 by targeting IGF-1 
could inhibit cell proliferation 






Mouse/human; 83 pairs of 
melanoma and ANCTs 
293 T, SK-mel- 
28, VMM917, 
NHEMs 
NRAS MAPK miR-145-5p by targeting NRAS 
could attenuate cell 
proliferation, migration, and 
invasion and enhance 
apoptosis in melanoma. 
[74] 
Rectal Cancer miR-195 Tumor 
Suppressor 





IGF1 _ miR-195 by targeting IGF1 
could attenuate tumor 
progression in rectal cancer via 
the PI3K/Akt pathway. 
[23] 
Colon Cancer miR-374a Tumor 
Suppressor 
Mouse/human; 90 pairs of 
colon cancer and ANCTs 
HCT116, SW620, 
SW480 
CCND1 EMT miR-374a by targeting 
CCND1could suppresses 
proliferation, migration, 
invasion, and intrahepatic 











Tiam1 EMT miR-29b by targeting Tiam1 
could decrease tumor growth, 
metastasis and EMT via PI3K/ 
Akt pathway. 
[76] 
CRC miR-1 Tumor 
Suppressor 
Mouse/human; 24 pairs of 





miR-1 by targeting LASP1 
could reduce EMT, metastasis, 
and tumor growth. 
[77] 
CRC miR-532 Tumor 
Suppressor 
Mouse/human; 58 pairs of 
CRC and ANCTs 
SW480, SW620, 
HCT116, HT29 
IGF-1R _ miR-532 by targeting IGF-1R 
could suppress proliferation, 
migration, and invasion in CRC 
cells. 
[78] 
Gastric Cancer (GC) miR-489 Tumor 
Suppressor 
52 pairs of GC and ANCTs SGC-7901, 
MKN45, GES-1 
HDAC7 EMT miR-489 by inhibiting HDAC7 
could suppress GC cell 
proliferation, invasion, and 
migration. 
[79] 
GC miR-107 Tumor 
Suppressor 
Mouse SGC-7901, MKN- 




BDNF _ miR-107 by targeting BDNF 
could inhibit GC cell 






83 pairs of GC and ANCTs MKN-45, SGC- 
7901, MGC-803, 
GES-1 
MTA2 EMT miR‑1236‑3p by targeting 
MTA2 could inhibit 
proliferation, invasion, and 
metastasis and suppress EMT 
in GC via the PI3K/Akt 
pathway. 
[81] 
GC miR-137 Tumor 
Suppressor 
Mouse/human; 107 pairs of 




Cox-2 _ miR-137 by targeting Cox-2 
could inhibit tumor growth in 
GC. 
[82] 
GC miR-183 Tumor 
Suppressor 









attenuate GC development and 
[83] 
(continued on next page) 
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rate of distant or regional metastasis, and larger tumor size. Functional 
assays have demonstrated the role of this miRNA in the suppression of 
bladder cancer cell viability and migration and induction of apoptosis 
through inactivation of the PI3K/AKT pathway [16]. miR-331-3p has 
been displayed to be down-regulated in nasopharyngeal carcinoma tis-
sues and cell lines. This miRNA impedes proliferation and invasion of 
nasopharyngeal carcinoma cells and enhances cell apoptosis via 
decreasing elF4B and subsequent inhibition of the phosphorylation of 
PI3K and AKT [17]. Fig. 2 illustrates the modulation of PI3K/AKT 
signaling pathway by various tumor suppressor miRNAs in different 
human cancers. 
4. Up-regulated PI3K/AKT-associated miRNAs in cancers 
Also, several oncogenic miRNAs accomplish their function through 
increasing activity of the PI3K/AKT pathway. For instance, miR-182 and 
miR-135b are up-regulated in colorectal cancer sections compared with 
the corresponding noncancerous tissues. ST6GALNAC2 has been iden-
tified as the direct target of these miRNAs. miR-182/-135b also enhances 
the activity of the PI3K/AKT pathway. Therefore, the miR-182/-135b/ 
ST6GALNAC2/PI3K/AKT axis has been proposed as a potential 
biomarker and therapeutic candidate in colorectal cancer patients [86]. 
Moreover, expression of miR-182 has been lower in postoperative serum 
specimens from patients with colorectal cancer, compared with preop-
erative serum specimens from these patients. Expression of this miRNA 
was further increased in serum samples of patients whose disorder 
recurred. Over-expression of this miRNA enhances cell proliferation, 
colony formation, augmented ki67 expression, and increased the inva-
siveness of cancer cells by up-regulating MMP-2 and MMP-9 expres-
sions. In addition, miR-182 binds with the 3’ UTR of DAB2IP and 
inhibits its expression. Thus, miR-182 acts as an oncogenic miRNA in 
colorectal cancer cells by affecting expression of DAB2IP, which possibly 
contributes to the induction of the PI3K/Akt/mTOR and Wnt/β-catenin 
[87]. Expression of miR-193 has been elevated in triple-negative breast 
neoplasm compared with non-tumor tissues and normal cell lines. 
Over-expression of this miRNA was associated with the poor prognosis 
of these patients. Mechanistically, this miRNA enhances cell prolifera-
tion and invasion through binding with the 3’ UTR of ING5 and 
modulating PI3K/AKT signaling pathway. miR-193 silencing suppresses 
cell invasion-mediated EMT as well [88]. Table 2 shows the function of 
oncomiRs in the regulation of the PI3K/AKT pathway. 
5. Diagnostic impact of PI3K/AKT-associated miRNAs 
Expression levels of PI3K/AKT-associated miRNAs are potential 
diagnostic markers in cancer patients. For instance, expression of the 
down-regulated miRNA, miR-337–3p can distinguish disease status in 
epithelial ovarian cancer tissues with an accuracy of 0.74 [46]. Besides, 
expression levels of these miRNAs can predict the survival of cancer 
patients. For example, down-regulation of miR-125b-3p, miR-320, 
miR-126, and miR-149 were associated with poor survival times of pa-
tients with bladder cancer, breast cancer, glioma, and ovarian cancer, 
respectively [16,18,35,47]. On the other hand, over-expression of 
miR-494-3p was associated with poor relapse-free survival and overall 
survival of patients with hepatocellular carcinoma [97]. Table 3 displays 
the results of studies that appraised the prognostic roles of 
PI3K/AKT-associated miRNAs in cancers. 
6. LncRNAs and PI3K/AKT pathway 
The functional link between dysregulation of lncRNAs and activation 
of PI3K/AKT pathway has been appraised in numerous studies. 
7. Down-regulated PI3K/AKT-associated lncRNAs in cancers 
Yao et al. have demonstrated down-regulation of lncRNA in osteo-
sarcoma cell lines and clinical samples. Functional studies revealed the 
role of this lncRNA in inhibition of cell proliferation and induction of 
apoptosis in a certain osteosarcoma cell line. Subsequent in silico and 
functional investigations demonstrated the impact of lncRNA 691 in the 
suppression of expression of miR-9-5p. Notably, PTEN has been shown 
to be a direct target of miR-9-5p. Thus, lncRNA 691/miR-9-5p can 
modulate the PTEN/PI3K/AKT pathway in osteosarcoma through 
regulation of PTEN expression [124]. Cao et al. have shown 
down-regulation of lncRNA ADAMTS9-AS2 in gastric cancer in associ-
ation with poor patients’ outcomes. The functional studies revealed the 
role of ADAMTS9-AS2 in inhibition of gastric cancer cell proliferation, 
suppression of migration and invasion, and activation of apoptosis 
through modulation of PI3K/Akt pathway [125]. Luo et al. have dis-
played under-expression of TCL6 in hepatocellular carcinoma (HCC) 
tissues compared with control samples. In HCC cell lines, the 
down-regulation of this lncRNA was accompanied by the up-regulation 
of miR-106a-5p. TCL6 has been shown to suppress cell proliferation, 
migration, and invasion of HCC cells through binding with miR-106a-5p 
and releasing PTEN from its inhibitory effects. miR-106a-5p silencing or 
TCL6 up-regulation enhanced the protein level of PTEN and inhibited 
phosphorylation of AKT and expression of PI3K protein [126]. Zhang 
et al. have detected decreased levels of LINC00982 in renal cancer 
samples compared with the adjacent non-cancerous tissues in associa-
tion with tumor size and TNM stage. Over-expression of LINC00982 
suppressed cell proliferation and enhanced apoptosis in renal cancer cell 
lines through modulation of PI3K/AKT activity [127]. Table 4 provides 
Table 1 (continued ) 
Cancer Type microRNA Role of 
microRNA 





enhance apoptosis and 
autophagy via PI3K/Akt/ 
mTOR pathway. 
GC miR-1254 Tumor 
Suppressor 
Mouse/human; 90 pairs of 





Smurf1 EMT miR-1254 by targeting Smurf1 
could suppress proliferation, 
migration, invasion, and EMT 
in GC. 
[84] 
GC miR-183 Tumor 
Suppressor 
TCGA dataset AGS, MKN-45 TCF12 _ miR-183 by targeting TCF12 
could enhance apoptosis and 
inhibit proliferation, 
migration, and invasion in GC. 
[85]  
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Table 2 
The function of oncogenic miRNAs on PI3K/AKT pathway in cancer (ANCTs: adjacent non-cancerous tissues).  
Cancer type microRNA Role of 
microRNA 









Oncogene Mouse/human; 33 




ST6GALNAC2 _ miR-182/-135b by targeting 
ST6GALNAC2 could enhance 
proliferation, migration, and 
invasion. 
[86] 
CRC miR-182 Oncogene Mouse/human; 
blood samples 
(CRC, n = 57), 
(healthy, n = 28), 
25 pairs of CRC and 
ANCTs 






miR-182 by targeting DAB2IP 
regulates cell proliferation, 
invasion, and tumor growth in 
CRC via regulating PI3K/Akt/ 
mTOR and Wnt/β-catenin 
cascades. 
[87] 




PTEN _ miR-106a by targeting PTEN 
could increase cell proliferation 
and inhibit apoptosis in CRC cells 





miR-193 Oncogene Mouse/human; 50 




ING5 EMT miR-193 by targeting ING5 could 
confer cell proliferation and 
invasion in TNBC cells. 
[88] 
TNBC miR-214 Oncogene 37 TNBC, 37 
healthy control, 37 
non-TNBC BCa 
MDA-MB-231 α1‑AT mTOR miR‑214 by targeting α1‑AT via 
PI3K/Akt/mTOR pathway could 
enhance proliferation, migration, 
and invasion in TNBC cells. 
[90] 
Breast Cancer (BC) miR-106b, 
miR-93 




PTEN  miR-106b and miR-93 by 
targeting PTEN could enhance 
cell proliferation, migration, and 




miR-21 Oncogene _ T24, THP‑1 PTEN, STAT3 - miR‑21 by inhibiting PTEN could 
active M2-type related genes in 
macrophages to enhance the 
invasion and migration of BCa 
cells via enhancing PI3K/Akt- 




Oncogene 17 pairs of BCa and 
ANCTs 
UMUC2, 5637 PTEN _ miR-103/107 by targeting PTEN 
could induce tumorigenicity in 
BCa cells via activating PI3K/Akt 
pathway. 
[93] 
Liver Cancer miR-21-3p Oncogene Mouse PLC, HepG2, Huh7, 
LO2 
PTEN, BAD _ miR-21-3p by targeting PTEN 
could attenuate TRAIL-mediated 





miR-616 Oncogene 123 pairs of HCC 
and ANCTs 
HepG2, THLE-3 PTEN _ miR-616 by targeting PTEN could 
contribute to malignant 
progression of HCC via activating 
PI3K/Akt pathway. 
[95] 
HCC miR-367 Oncogene 126 pairs of HCC 
and ANCTs 
HepG2, THLE-3 PTEN _ miR-367 by targeting PTEN could 
contribute to malignant 











PTEN _ MiR-494-3p by targeting PTEN 
could enhance proliferation, 





Oncogene 43 pairs of HCC and 
ANCTs, TCGA 
dataset 





PTEN _ miR-3691-5p by regulating PTEN 
could promote HCC cell 
migration and invasion through 




Oncogene Mouse/human; 20 





PLC/5, chang liver 
PTEN _ miR-106b-5p by targeting PTEN 
increases HCC stemness 
maintenance and metastasis. 
[99] 
HCC miR-221 Oncogene _ PLC/PRF/5, Huh7, 
HepG2, SNU-449, 
SNU-423, SK-Hep-1 
CD44 mTOR miR-221 by targeting CD44 could 







miR-17-5p Oncogene Mouse/human; 39 
pairs of LSCC and 
ANCTs 
HEp-2, SCC-2, SCC- 
40, HOK 
PIK3R1 _ miR-17-5p by targeting PIK3R1 
could participate in LSCC cell 
proliferation and apoptosis via 
deactivating PI3K/Akt pathway. 
[101] 
Osteosarcoma (OS) miR-191- 
5p 
Oncogene Mouse/human; 63 




EGR1 EMT miR-191-5p by inhibiting EGR1 
could promote cell proliferation, 
migration, and invasion in OS via 
EMT and PI3K/Akt signaling 
pathways. 
[102] 
Lung Cancer miR-200 Oncogene FOG2 _ [103] 
(continued on next page) 
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Table 2 (continued ) 
Cancer type microRNA Role of 
microRNA 





33 pairs of lung 
cancer and ANCTs 
HCC827zeb1, 
344SQ 
miR-200 by targeting FOG2 could 









PTEN _ miR-4286 by targeting PTEN 
could promote cell proliferation, 
migration, and invasion. 
[104] 
NSCLC miR-21 Oncogene Mouse HBE, A549 ASPP2 NF-κB, EMT miR-21 by targeting ASPP2 could 
inhibit apoptosis and induce cell 
migration, invasion, and EMT in 
NSCLC cells via PI3K/Akt and NF- 
κB cascades. 
[105] 
Gastric Cancer (GC) miR-107 Oncogene Mouse/human; 
150 pairs of GC and 
ANCTs 
GES-1, AGS, KATO- 
III, MGC-803, MKN- 
45, MKN-28, 
HGC27, NS-3 
FAT4 EMT miR-107 by targeting FAT4 could 
promote proliferation, migration 
invasion, and tumorigenicity in 
GC cells via regulating EMT and 
PI3K/Akt pathways. 
[106] 
GC miR-21 Oncogene _ MKN74 PTEN mTOR miR-21 by targeting PTEN could 
increase cell proliferation, 
migration, and invasion in GC 
cells via PI3K/Akt/mTOR. 
[107] 
GC miR-28 Oncogene 31 pairs of GC and 
ANCTs 
SGC-7901, MGC- 
803, MKN-1, BGC- 
823, AGS 
PTEN _ miR-28 by targeting PTEN 
enhances cell proliferation and 
invasion. 
[108] 
GC miR-592 Oncogene Mouse/human; 70 
pairs of GC and 
ANCTs 
SGC7901, BGC823, 




MiR-592 by targeting Spry2 
could promote GC proliferation, 





miR-222 Oncogene Mouse C918, MUM-2B _ _ HMGA1/miR-222 axis could 
promote cell proliferation, 
migration, and tumor progression 





miR‑182 Oncogene Mouse/human; 22 
RB and 34 normal 
retinal tissues 
Y79, WERI-Rb-1 CADM2 _ miR‑182 by targeting CADM2 
could promote cell viability, 
invasion, and angiogenesis in RB. 
[111] 
Diffuse Large B-Cell 
Lymphoma 
(DLBCL) 






FOXO1, PTEN mTOR miR-21 by targeting FOXO1 and 
PTEN could inhibit proliferation, 
migration, and invasion in 
DLBCL. 
[112] 
Melanoma miR-25 Oncogene _ M14, A875, MV3, 
uacc257, HEM-a 
RBM47 mTOR miR-25 by targeting RBM47 
could promote melanoma 





miR-451 Oncogene Mouse NCI-H929, 
RPMI8226, KMS-11, 
LP-1, U266, SKO 
TSC1 mTOR miR-451 by targeting TSC1 could 
regulate the stemness of side 
population cells in MM. 
[114] 
MM miR‑20a Oncogene 30 MM plasma 




PTEN _ miR‑20a by targeting PTEN could 
enhance cell proliferation and 







miR-18a Oncogene _ TE13, Eca109 PTEN, Cyclin 
D1 
mTOR miR-18a by suppression of PTEN 
increases expression of Cyclin D1 
thus promoting the cell cycle 
progression of ESCC cells via 
PI3K/Akt/mTOR pathway. 
[116] 
ESCC miR-214 Oncogene Mouse/human; 30 




LZTS1 mTOR miR-214 by targeting LZTS1 
could promote cell metastasis and 







265 NPC tissues 
(184 EBV positive, 
81 EBV negative), 
36 non-NPC tissues 
CNE1, CNE2, C666- 
1, HONE1, HNE1, 
293 T 
PTEN EMT miR-144-3p by targeting PTEN 
could compel EMT and facilitate 
NPC via PI3K/Akt pathway. 
[118] 
NPC miR-155 Oncogene _ CNE2 PTEN _ miR-155 by targeting PTEN could 
promote proliferation and inhibit 
apoptosis in NPC cells. 
[119] 
Pituitary Adenoma miR-106b Oncogene 55 pituitary 
adenoma tissues 
and 8 normal 
pituitary tissues 
AtT-20 PTEN _ miR-106b by targeting PTEN 








110 FTC tissues and 




ST8SIA4 mTOR miR-146a/b by targeting 
ST8SIA4 could promote 
proliferation, migration and 
invasion in FTC cells via PI3K/ 
Akt/mTOR signalling pathway. 
[121] 
miR-34a Oncogene TPC-1 GAS1, Bad _ [122] 
(continued on next page) 
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the brief summary of the effects of tumor suppressor lncRNAs in the 
regulation of the PI3K/AKT pathway in cancer. 
8. Up-regulated PI3K/AKT-associated lncRNAs in cancers 
Several oncogenic lncRNAs accomplish their carcinogenic effects 
through activation of the PI3K/AKT pathway. For instance, Wang et al. 
have shown up-regulation of lncRNA RP1-93H18.6 in cervical cancer 
cells and tissues. This lncRNA has been shown to enhance the activity of 
the P13K/AKT pathway. Functional and in vivo studies indicated that 
inhibition of lncRNA RP1-93H18.6 attenuated the initiation and pro-
gression of cervical cancer via blocking the PI3K/AKT pathway [146]. 
Qu et al. have reported up-regulation of HOXA-AS2 in acute myeloid 
leukemia (AML) patients in correlation with greater white blood cell and 
bone marrow blast counts, unfavorable cytogenetic abnormalities, more 
quantifiable residual disease positivity, and poor prognosis. Moreover, 
Table 2 (continued ) 
Cancer type microRNA Role of 
microRNA 







25 pairs of PTC and 
ANCTs 
miR-34a by targeting GAS1 could 
promote cell proliferation and 
inhibit apoptosis in PTC cells. 
Ovarian Cancer 
(OC) 
miR-21 Oncogene _ IOSE80, A2780, 
SKOV-3 
PTEN _ miR-21 by targeting PTEN could 




Prognostic role of PI3K/AKT-associated miRNAs in cancers.  
Sample Number Kaplan-Meier Analysis Univariate Cox Regression Multivariate Cox Regression Refs. 
52 BCa patients Low amounts of miR-125b-5p were associated 
with shorter OS. 
- - [16] 
52 GC patients Low amounts of miR-489 were associated 
with poorer OS and PFS. 
- - [79] 
72 OC patients Low amounts of miR-149 were associated 
with shorter OS. 
- - [47] 
49 NSCLC patients Low amounts of miR-874 were associated 
with shorter OS. 
- - [69] 
50 TNBC patients High amounts of miR-193 were associated 
with shorter OS. 
- - [88] 
52 BC patients Low amounts of miR-320 were associated 
with shorter OS. 
- - [18] 
39 LSCC patients High amounts of miR-17-5p were associated 
with sorter OS. 
- - [101] 
44 glioma patients Low amounts of miR-126 were associated 
with shorter OS. 
- - [35] 
63 OS patients High amounts of miR-191-5p were associated 
with shorter OS. 
- - [102] 
28 BCa patients Low amounts of miR-328-3p were associated 
with shorter OS. 
- - [15] 
54 LA patients Low amounts of miR-381 were associated 
with shorter OS. 
- - [65] 
369 HCC patients 
from TCGA 
dataset 
High amounts of miR-3691-5p were 
associated with shorter OS. 
- - [98] 
61 HCC patients Low amounts of miR-944 were associated 
with shorter DFS and OS. 
- - [37] 
110 HCC patients Low amounts of miR-300 were associated 
with shorter OS and DFS. 
Low expression of miR-300 was correlated 
with advanced Edmondson-Steiner 
grades. 
Low expression of miR-300 was correlated with 
tumor number, vascular invasion, and advanced 
BCLC stage. 
[38] 
223 PCa from TCGA 
dataset 
Low amounts of miR-133a-3p were associated 
with shorter bone metastasis-free survival and 
PFS. 
- Low expression of miR-133a-3p was correlated with 
lymph node involvement. 
[59] 
85 NSCLC patients Low amounts of miR-409 were associated 
with shorter OS and DFS. 
- - [68] 
271 HCC patients High expression of miR-494-3p were 
associated with shorter RFS and OS. 
- - [97] 
49 GBC patients Low amounts of miR-143-3p were associated 
with shorter OS. 
- - [55] 
126 HCC patients Low amounts of miR-1296 were associated 
with shorter OS and DFS. 
- - [40] 
60 glioma patients Low amounts of miR-489 were associated 
with shorter OS. 
- Low amounts of miR-489 were correlated with 
advanced WHO grades. 
[36] 
90 colon cancer 
patients 
Low amounts of miR-374a were associated 
with shorter OS. 
- Low amounts of miR-374a were correlated with 
lymph node involvement. 
[75] 
200 DLBCL patients High amounts of miR-21 were associated with 
shorter OS. 
- High amounts of miR-21 were correlated with poor 
R-IPI index. 
[112]  
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Table 4 
The function of tumor suppressor lncRNAs in the regulation of PI3K/AKT pathway in cancer (ANCTs: adjacent non-cancerous tissues).  













17 pairs of OS 
and ANCTs 




_ LncRNA 691 by targeting miR-9-5p 
could inhibit cell viability, 
proliferation, and promote 
apoptosis in OS cells. 
(124) 




pairs of OS and 
ANCTs 
hFOB1.19, Saos2, 




_ GAS5 by targeting miR-23a-3p 
could suppress proliferation and 
invasion of OS cells via PTEN/ 
PI3K/Akt axis. 
(128) 
OS FER1L4 Tumor 
Suppressor 
30 pairs of OS 
and ANCTs 
hFOB1.19, MG63, 
U2OS, HOS, Saos-2 
miR-18a-5p, 
SOCS5 
EMT FER1L4 by targeting miR-18a-5p/ 
SOCS5 could induce apoptosis and 
suppress EMT via activating PI3K/ 
Akt pathway in OS. 
(129) 
OS LINC00628 Tumor 
Suppressor 
80 pairs of OS 
and ANCTs 
NHOst, HOS, MG-63, 
SOSP-9607, U2OS 
_ _ LINC00628 could inhibit 
proliferation, invasion, and 
migration and also promote 
apoptosis in OS cells through 














_ MAPK/ERK PICART1 could inhibit cell 
proliferation and inhibit apoptosis 
via PI3K/Akt and MAPK/ERK 
signaling pathways in GC. 
(131) 









_ mTOR LOC101928316 could attenuate 
proliferation, migration, and 
invasion in GC cells via PI3K/Akt/ 
mTOR pathway. 
(132) 
GC ADAMTS9-AS2 Tumor 
Suppressor 
71 pairs of GC 
and ANCTs 
GES-1, MKN74, SGC- 
7901, NUGC-4, HGC- 
27 
_ _ ADAMTS9-AS2 could inhibit GC 
cell proliferation, migration and 
invasion, and induce apoptosis. 
(125) 




pairs of GC and 
ANCTs 





_ SLC25A5-AS1 by targeting miR- 
19a-3p could inhibit cell 
proliferation, cell cycle 
progression, and promote apoptosis 
via PTEN/PI3K/AKT axis in GC. 
(133) 




pairs of glioma 
and ANCTs 
U-251, M059J miR-93 _ MEG3 by targeting miR-93 could 
inhibit cell growth and induce 







28 pairs of CRC 
and ANCTs 
SW480 _ _ AB073614could prevent 
proliferation and metastasis of CRC 
cells. 
(135) 




pairs of CRC 
and ANCTs 
SW480, SW620, 
LOVO, U937, HL60, 
SW1353, HeLa, 293 
T, ACHN, HepG2, 
MCF-7 
_ _ ST3Gal6-AS1 could inhibit CRC cell 
proliferation, metastasis, and 
promote apoptosis by modulating 
α-2,3 sialylation. 
(136) 
CRC SNHG6 Tumor 
Suppressor 




ETS1 mTOR SNHG6 by targeting ETS1 could 
inhibit cell proliferation and 
metastasis via PI3K/Akt/mTOR 
signaling pathways. 
(137) 
CRC LINC02381 Tumor 
Suppressor 
20 pairs of CRC 
and ANCTs/ 
TCGA dataset 




PTEN _ LINC02381 by regulating PTEN 
could inhibit cell proliferation and 









pairs of BCa 
and ANCTs 





_ LINC00641by targeting miR-197- 
3p/KLF10 could attenuate 
proliferation, migration, and 








GEO database HepG2, 293 T, 
SMCC-7721, MHCC- 
97H, HUH7, LO2 
miR-106a- 
5p, PTEN 
_ TCL6 by targeting miR-106a-5p 
could attenuate proliferation, 
migration, and invasion in HCC via 
PTEN/PI3K/Akt axis. 
(126) 
HCC FER1L4 Tumor 
Suppressor 






_ _ FER1L4 could suppress 
proliferation and migration in HCC 









293 T, Y79, Weri- 
Rb1, RB44 
PI3Kγ _ CANT1 by directly binding to the 
PI3Kγ promoter could suppress 
tumor progression in RB via the 
PI3K/Akt pathway. 
(141) 
Lung Cancer FER1L4 Tumor 
Suppressor 
_ _ (142) 
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expression of this lncRNA was an independent prognostic factor in AML 
patients with the normal karyotype. In vitro investigations demon-
strated that knock-down of this lncRNA resulted in inhibition of growth 
of leukemic cells through stimulation of cell cycle arrest and apoptosis. 
Moreover, HOXA-AS2 silencing decreased phosphorylation of PI3K and 
AKT therefore enhanced expression of P21 and P27. SOX4 has been 
suggested as one of the main targets of this lncRNA in AML [147]. Wei 
et al. have reported over-expression of BCAR4 in glioma tissues 
compared with paired non-tumor samples. Up-regulation of this lncRNA 
was correlated with short overall survival of these patients. BCAR4 
silencing suppressed cell proliferation, while its up-regulation enhanced 
proliferation of glioma cells. Mechanistically, BCAR4 induces PI3K/AKT 
signaling via enhancing the expression of EGFR. Taken together, BCAR4 
enhances progression of glioma through promoting activity of EGFR/-
PI3K/AKT axis [148]. Han et al. have assessed the expression profile of 
CASC11 in HCC samples from the Cancer Genome Atlas (TCGA) data-
base. They reported an association between over-expression of CASC11 
poor overall survival rate of HCC patients. Subsequently, they confirmed 
these results in another set of HCC patients. CASC11 silencing inhibited 
cell migration, invasion, and EMT. Expression of this lncRNA was 
induced by the transcription factor STAT3. CASC11 was shown to 
decrease expression of PTEN through binding with EZH2 [149]. Fig. 3 
represents dysregulation of a number of lncRNAs which have a 
remarkable oncogenic role via reguklating PI3K/AKT signaling cascade. 
9. Biomarker role of PI3K/AKT-associated lncRNAs 
PI3K/AKT-associated lncRNAs have been shown to have the poten-
tial to be used as diagnostic/ prognostic markers. For instance, 
SLC25A5-AS1, TINCR, MALAT1, and have diagnostic power values of 
0.76, 0.92, and 0.95 in gastric, colorectal, and squamous cell carcinoma 
patients, respectively [203,208,214]. Moreover, LINC00265 had a 
diagnostic value of 0.81 in AML patients [164]. Over-expression of 
several lncRNAs such as HOXA-AS2, HAGLROS, HOTTIP, and MALAT1 
has been recognized as markers for poor survival of cancer patients 
[147,153,199,202]. Table 6 summarizes the results of studies that 
evaluated the diagnostic or prognostic potential of PI3K/AKT-associated 
lncRNAs in human malignancies. 
10. Discussion 
PI3K/AKT signaling participates in the phosphorylation of numerous 
molecules that control cell growth, proliferation, metabolism, and sur-
vival. This pathway is commonly activated in human malignancies [2]. 
Accordingly, several inhibitors have been designed to target kinases in 
this pathway and their efficacy is being assessed in clinical trials. Yet, 
their effectiveness can be restricted by some mechanisms such as FOXO- 
and mTORC1-associated feedback loops that reactivate this pathway 
[2]. NcRNAs contribute to the regulation of several proteins in the 
PI3K/AKT pathway including proteins that mediate these feedback 
loops [112], thus identification of the exact function of ncRNAs would 
facilitate the design of targeted therapies against this pathway with 
higher efficiencies in the treatment of cancer patients. 
The effects of ncRNAs in the regulation of the PI3K/AKT pathway has 
been vastly assessed in solid tumors. However, this research avenue has 
been less explored in leukemia/ lymphoma. Based on the importance of 
inhibitors of this pathway in the treatment of patients with leukemia or 
lymphoma [215,216], identification of the role of ncRNAs in the regu-
lation of the PI3K/AKT pathway in these malignancies would facilitate 
recognition of the mechanisms of resistance to these kinds of treatments 
in these patients. A number of these ncRNAs influence activity of other 
cancer-related pathways such as Wnt/β-catenin, mTOR, and NF-κB 
pathways, thus providing a functional link between these signaling 
pathways. Besides, the EMT process is an essential cellular process that 
is influenced by these ncRNAs. Thus, therapeutic intervention with the 
expression of these ncRNAs is expected to affect the invasive properties 
of cancer cells. 
Notably, activation of the PI3K/AKT/mTOR pathway influences the 
response of cancer cells to chemotherapeutic agents and endocrine 
therapies through modulation of autophagy [217,218]. Therefore, 
ncRNAs that modulate the activity of this pathway have practical sig-
nificance in the determination of the response of patients to a wide range 
of therapeutic modalities. These transcripts also modulate the EMT 
process and cancer stem cell phenotype through regulation of expression 
of PTEN and several EMT-associated genes [219,220], thus influencing 
metastatic potential, invasiveness, and cancer recurrence. Moreover, 
PI3K/AKT-associated ncRNAs can predict the clinical ouutcome of 
patienst with diverse neoplastic conditions, emphasizing their prom-
innet roles in the pathogenesis of neoplasms. Both lncRNAs and miRNAs 
can be detected in the peripheral blood, urine samples or other body 
Table 4 (continued ) 









100 pairs of 
lung cancer 
and ANCTs 
BEAS-2B, 95D, SPC- 
A-1, A549, H1975, 
H-125 
FER1L4 could inhibit cell 
proliferation and metastasis in lung 
cancer cells. 












_ FOXO1 could inhibit lung cancer 
cell growth by downregulating the 
PI3K/Akt signaling pathway. 
(143) 









miR-21 Glycolysis MEG3 by targeting miR-21 could 
inhibit tumorigenesis and 
glycolysis in BC cells via the PI3K/ 
Akt pathway. 
(144) 
Renal Cancer (RC) LINC00982 Tumor 
Suppressor 
96 pairs of RC 
and ANCTs 
HK-2, 786-O, 769-P, 
ACHN, A-498 
_ _ LINC00982 could inhibit cell 
proliferation and promote 
apoptosis through PI3K/Akt 







human; 97 MM 







_ OIP5-AS1 by suppressing miR-410/ 
KLF10 could inhibit cell 
proliferation and apoptosis in MM. 
(145)  
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Fig. 3. A schematic summary of lncRNAs triggering various human cancers via the PI3K/AKT signaling pathway. Over-expression of various lncRNAs could 
play an important role in cancers via changing activity of PI3K/AKT cascade. Aberrant expression of different lncRNAs like CCAT1, OGFRP1, TTN-AS1, HAGLROS, 
FoxD2-AS1, and ASBEL could result in tumorigenesis of cervical cancer, endometrial cancer, lung adenocarcinoma, nasopharyngeal carcinoma, glioma, and oste-
osarcoma through directly targeting Runx2, miR-124-3p, SIRT1, PTEN, miR-100, ATG14, miR-185-5p, HMGA2, miR-21, PP2A, and GSK3β via PI3K/AKT signaling 
pathway. Therefore, suppressing the expression level of these oncogenes may be regarded as a helpful approach for the management of these cancers [150–157]. 
Table 5 shows the function of oncogenic lncRNAs in the regulation of the PI3K/AKT pathway in cancer. 
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Table 5 
The function of oncogenic lncRNAs in the regulation of PI3K/AKT pathway in cancer (ANCTs: adjacent non-cancerous tissues).  
Cancer type lncRNA Role of 
lncRNA 





Cervical Cancer (CC) RP1- 
93H18.6 
Oncogene Mouse/human; 78 




Caski, 293 T, C- 
33A 
_ _ RP1-93H18.6 could enhance 
proliferation, migration, and 
invasion and also induce 
metastasis. 
[146] 
CC CCAT1 Oncogene Mouse/human; 23 
pairs of CC and ANCTs 
HeLa, SiHa Runx2 EMT CCAT1 by targeting Runx2 
could inhibit proliferation and 
EMT of CC cells via the PI3K/ 
Akt pathway. 
[158] 
CC LINC01305 Oncogene _ SiHa, Hela, C- 
33A, Caski, ME- 
180, MS751 
TNXB EMT LINC01305 by targeting TNBX 
could enhance EMT, invasion, 
and migration in CC. 
[159] 
CC MFI2 Oncogene Mouse/human; 35 




_ _ MFI2 could promote cell 
proliferation, metastasis, and 
inhibit apoptosis in CC via the 
PI3K/Akt signaling pathway. 
[160] 





_ _ ANRIL could enhance 
proliferation, migration, and 
invasion in CC. 
[161] 
Ovarian Cancer (OC) MALAT1 Oncogene Mouse/human; 64 EOC 






_ EMT MALAT1 could promote 
proliferation, metastasis, and 
EMT in EOC. 
[162] 
Endometrial Cancer OGFRP1 Oncogene 48 pairs of endometrial 







_ OGFRP1 by targeting miR-124- 
3p/SIRT1 could enhance 
migration, invasion, and inhibit 
apoptosis via activating PI3K/ 
Akt/GSK-3β axis. 
[151] 
Endometrial Cancer LINP1 Oncogene Mouse/human; 35 
pairs of endometrial 
cancer and ANCTs 
KLE, AN3CA, 
ECC-1, T-HESC 
_ _ LINP1 could increase cell 





HOXA-AS2 Oncogene 108 Bone marrow (BM) 







SOX4 P21, P27 HOXA-AS2 by targeting SOX4 
could promote the proliferation 
of leukemic cells and repress 
cell apoptosis via the PI3K/Akt 
signaling pathway. 
[147] 
AML LINC00265 Oncogene 135 BM and PBS of 
AML patients 
HL-60, NB4, HS-5 _ _ LINC00265 could promote AML 
cell proliferation, migration, 
invasion, and suppress 









_ HULC by targeting miR-200a/ 
c-Myc could promote cell 
proliferation and oncogenesis 
in CML. 
[165] 





_ mTOR OECC could promote cell 
proliferation and metastasis via 
the PI3K/Akt/mTOR signaling 
pathway in lung cancer. 
[166] 
Lung Cancer HOXB-AS3 Oncogene Mouse/human; 30 





_ _ HOXB-AS3 regulates 
proliferation, metastasis, and 





TTN-AS1 Oncogene _ BEAS-2B, H157, 
HCC827, H1975, 
H1299, A549 
PTEN _ TTN-AS1 by destabilizing PTEN 
could promote progression of 
LAD via PI3K/Akt signaling 
pathway 
[152] 





PTEN EMT STAT3-induced CASC11 by 
targeting PTEN could promote 
cell migration, invasion, and 
EMT in HCC via activating 
PI3K/Akt signaling pathway. 
[149] 
HCC LINC00152 Oncogene Mouse/human; 70 







mTOR LINC00152 by targeting miR- 
139/PIK3CA could promote 
proliferation, migration, and 
invasion and also inhibit 
apoptosis in HCC. 
[168] 






MALAT1 by targeting miR- 
146a could inhibit apoptosis 




HCC LINC01133 Oncogene Mouse HepG2, Hep3B, 
MHCC-97 L, SK- 
_ _ LINC01133 could enhance 
proliferation, migration, and 
[170] 
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Table 5 (continued ) 
Cancer type lncRNA Role of 
lncRNA 







invasion, and also inhibit 
apoptosis in HCC via PI3K/Akt. 








PTEN EMT NR027113 by targeting could 
enhance proliferation, 
migration, and invasion in HCC 





Oncogene Mouse/human; 100 







mTOR CDKN2B-AS1 by targeting let- 
7c-5p/NAP1L1 could promote 
tumor growth and metastasis in 
HCC via PI3K/Akt/mTOR 
signaling pathway. 
[172] 
HCC PTTG3P Oncogene Mouse/136; HCC and 
ANCTs 
HepG2, Hep3B PTTG1 EMT PTTG3P by targeting PTTG1 
could promote cell growth, 
metastasis and inhibit 
apoptosis via PI3K/Akt 
signaling in HCC. 
[173] 
HCC CRNDE Oncogene Mouse/human; 23 






CRNDE could promote HCC cell 
proliferation by regulating the 
PI3K/Akt/GSK3β-Wnt/ 





SNHG1 Oncogene Mouse/human; 46 




_ _ SNHG1 enhances PDAC 
tumorigenesis by inducing 
PI3K/AKT signaling pathway. 
[175] 
Pancreatic Cancer (PC) HULC Oncogene 26 pairs of PC and 
ANCTs 
Panc-1 miR-15a _ HULC by targeting miR-15a 
could promote proliferation, 
migration, and invasion of 





Oncogene 147 pairs of PC and 
ANCTs 




_ EMT ABHD11-AS1 could promote 
proliferation, migration, 
invasion, and EMT in PC via 




SOX2-OT Oncogene Mouse/human; 82 






SOX2, PTEN _ IRF4-induced SOX2-OT by 
targeting SOX2 could promote 
the progression of CCA via 
activating the PI3K/Akt 
signaling pathway. 
[178] 
Thyroid Cancer (TC) H19 Oncogene 30 pairs of TC and 
ANCTs 
FTC-133, TPC-1 _ _ H19 could enhance cell 
viability and inhibit apoptosis 
of TC cells 
[179] 
TC XIST Oncogene Mouse/human; 77 




miR-34a MET XIST by targeting miR-34a 
could enhance cell proliferation 
and tumor growth in thyroid 







Oncogene Mouse/human; 82 
pairs of PTC and ANCTs 
BCPAP, Nthy-ori 




_ STAT3-induced ABHD11-AS1 
by targeting miR-1301-3p/ 
STAT3 could promote tumor 
progression in PTC via PI3K/ 
Akt signaling pathway. 
[181] 







mTOR ZEB1-AS1 by regulating miR- 
342-3p/CUL4B could increase 
proliferation, migration, and 
invasion in PCa via PI3K/Akt/ 
mTOR pathway. 
[182] 
Non-Small Cell Lung 
Carcinoma (NSCLC) 
NORAD Oncogene Mouse/human; 26 
pairs of NSCLC and 
ANCTs 
NHBE, 293 T, 
A549, H1299, 




mTOR NORAD by targeting miR-520a- 
3p could enhance proliferation, 
migration, and invasion. 
[183] 
NSCLC CRNDE Oncogene Mouse/human; 30 
pairs of NSCLC and 
normal control tissues 
A549, PC-9, SK- 
MES-1, 16HBE 
_ _ CRNDE could promote cell 
proliferation through PI3K/Akt 












HAGLROS by targeting miR- 
100/ATG14 could confer cell 
viability, autophagy and 
enhance apoptosis via PI3K/ 
Akt/mTOR. 
[153] 
Glioma BCAR4 Oncogene 92 pairs of glioma and 
ANCTs 
U87, U251, 
LN229, T98 G, 
NHAs 
EGFR _ BCAR4 could promote glioma 
cell proliferation and inhibit 
apoptosis via EGFR/PI3K/AKT 
cascade. 
[148] 




LSINCT5 by targeting miR-451 
could confer glioma cells 
[185] 
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Table 5 (continued ) 
Cancer type lncRNA Role of 
lncRNA 








growth and metastasis via 
inhibiting Rac1-regulated 
PI3K/AKT, Wnt/b-catenin, and 
NF-κB pathways. 
Glioma FoxD2-AS1 Oncogene Mouse/human; 48 G 
tissues, and 24 healthy 
normal control/ GEO 
database 
U87, A172, 




_ FoxD2-AS1by targeting miR- 
185-5p/HMGA2 could promote 
tumor progression and 
metastatic potential of glioma 
cells. 
[154] 
Glioma SNHG20 Oncogene 80 pairs of G and 
ANCTs 
U118, U251 _ _ SNHG20 by targeting PTEN 
could decrease apoptosis and 
induce cell proliferation in 
glioma via PI3K/Akt signaling 
pathway. 
[186] 






_ _ LINC01426 could confer 
glioma cells proliferation, 
migration, and invasion, and 
induce apoptosis. 
[187] 
Osteosarcoma (OS) UCA1 Oncogene Mouse/human; 30 
pairs of OS and ANCTs 
hFOB1.19, Saos- 
2, HOS, U2-OS, 
MG-63 
CREB1 EMT, mTOR UCA1 by targeting CREB1 
could promote OS invasion and 









_ _ DBH-AS1 could inhibit cell 
proliferation, migration, and 
invasion, and also promote 
apoptosis in OS. 
[189] 
OS ANRIL Oncogene Mouse/human; 57 
pairs of OS and ANCTs 
MNNG/HOS, 
U2OS 
_ _ ANRIL could promote 
tumorigenesis in OS cells via 
the PI3K/Akt signaling 
pathway. 
[190] 





MEK/ERK ASBEL by targeting miR-21/ 
PP2A could promote 
proliferation, migration, and 
invasion in OS via regulating 
PI3K/AKT/GSK3β and MEK/ 
ERK signaling pathways. 
[155] 
OS LINC00968 Oncogene Mouse U2OS, MG63, 
Saos-2, 143-B, 
SW1353, hFOB 
_ mTOR LINC00968 could increase cell 
proliferation, migration, and 
invasion. 
[191] 
OS MALAT1 Oncogene Mouse/human; 68 
pairs of OS and ANCTs 
MG63, U2OS, 







_ MALAT1 by targeting miR-129- 
5p/RET could promote 
proliferation and migration in 
OS via the PI3K/Akt pathway. 
[192] 





_ _ MIAT could promote melanoma 
migration and invasion. 
[193] 
Melanoma OR3A4 Oncogene 50 melanoma tissues 





_ _ OR3A4 could promote invasion 
and migration in melanoma by 
inducing PI3K/Akt cascade. 
[194] 
Melanoma MHENCR Oncogene Mouse/human; 30 
pairs of melanoma and 
ANCTs 
A375, SK-MEL-2 miR-425/- 
489 
_ MHENCR by targeting miR- 
425/-489 could enhance 
proliferation, induce cell cycle 
arrest and apoptosis, and also 
reduce melanoma growth and 
metastasis. 
[195] 
Melanoma HOTAIR Oncogene Mouse/human; 60 
pairs of melanoma and 
ANCTs 





mTOR HOTAIR by targeting miR-152- 
3p/c-MET could enhance tumor 
growth and metastasis via 
PI3K/Akt/mTOR pathway. 
[196] 





_ NF-κB H19 could inhibit migration 
and invasion of melanoma cells 
by inactivating NF-κB and 
PI3K/Akt cascades. 
[197] 
Clear Cell Renal Cell 
Carcinoma (ccRCC) 




KISS1 mTOR TP73-AS1 by repressing KISS1 
could promote cell 
proliferation and inhibit 




Renal Cell Carcinoma 
(RCC) 
HOTTIP Oncogene Mouse/human; 42 




Atg13 autophagy HOTTIP by regulating 
autophagy could increase RCC 
[199] 
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fluids, representing their position in non-invasive diagnosis of neoplastic 
conditions. 
LncRNAs regulate the activity of the PI3K/AKT pathway through 
different mechanisms among them is acting as competing endogenous 
RNAs for miRNAs. Several pairs of lncRNA/ miRNA have been recog-
nized that modulates the function of this pathway in different types of 
cancers, for instance, lncRNA 691/miR-9-5p and GAS5/miR-23a-3p in 
osteosarcoma [124,128], MEG3/miR-21 in breast cancer [144] and 
TCL6/miR-106a-5p in HCC [126]. Thus, the functional interaction be-
tween these two kinds of ncRNAs is a well-recognized mechanism for 
induction or suppression of this pathway. Any putative targeted therapy 
against the PI3K/AKT pathway should consider the complex interactions 
between miRNAs and lncRNAs. The miRNA/lncRNA/mRNA trios in the 
context of PI3K/AKT signaling can be used as therapeutic targets for 
efficiently modulating activity of this molecular axis. 
PIK3/AKT-associated ncRNAs have the potential to be applied as 
diagnostic/ prognostic biomarkers in cancer patients. Based on the 
functional link between these transcripts, it is expected that a combi-
nation of expression levels of a number of these ncRNAs would facilitate 
the design of diagnostic/prognostic panels with high accuracies. 
Table 5 (continued ) 
Cancer type lncRNA Role of 
lncRNA 





progression via the PI3K/Akt/ 
Atg13 axis. 





miR-22-3p _ MALAT1 by targeting miR-22- 
3p could enhance proliferation, 
migration, and mobility in RCC. 
[200] 
Retinoblastoma (RB) H19 Oncogene _ Y79 miR-143, 
RUNX2 
mTOR H19 by targeting miR-143/ 
RUNX2 could enhance 
proliferation, migration, 
invasion, and inhibit apoptosis 
via PI3K/Akt/mTOR. 
[201] 
Gastric Cancer (GC) MALAT1 Oncogene 64 pairs of GC and 
ANCTs, and 64 healthy 
normal control 
SNU-1, AGS _ _ MALAT1 could promote 
proliferation, migration, and 




TINCR Oncogene Mouse/human; 80 





miR-7-5p mTOR TINCR by targeting miR-7-5p 
could enhance proliferation, 
migration, invasion, and induce 
metastasis in CRC via PI3K/ 
Akt/mTOR signaling pathway. 
[203] 
CRC DLX6-AS1 Oncogene Mouse/human; 60 





_ mTOR DLX6-AS1 could promote cell 
proliferation, invasion, and 
migration via modulating 
PI3K/Akt/mTOR pathway. 
[204] 







mTOR SNHG7 by targeting miR-34a/ 
GALNT7 could enhance 
proliferation, migration, and 
invasion in CRC via PI3K/Akt/ 
mTOR pathway. 
[205] 
CRC LINC01296 Oncogene Mouse/human; 36 








_ LINC01296 by targeting miR- 
26a/GALNT3 could develop 
CRC progression by regulating 
O-glycosylated MUC1. 
[206] 
CRC PlncRNA-1 Oncogene Mouse/human; 77 





_ _ PlncRNA-1 could promote CRC 




Tongue Squamous Cell 
Carcinoma (TSCC) 
MALAT1 Oncogene 72 pairs of OSCC and 
ANCTs 
SCC4, SCC15, 
SCC25, Hs 680. 
Tg 
MMP-9 _ MALAT1 by regulating MMP-9 
could confer tumor growth in 
TSCC via PI3K/Akt signaling 
pathway. 
[208] 
Oral Squamous Cell 
Carcinoma (OSCC) 







FTH1P3 could promote OSCC 








Oncogene Mouse/human; 102 






MEK/ERK ADAMTS9-AS2 by targeting 
miR-143-3p/ITGA6 could 
promote proliferation, 
migration, invasion, and 
metastasis in SACC. 
[210] 







_ EMT LOXL1-AS1 could promote 
proliferation, metastasis, and 
EMT in medulloblastoma via 





CASC9 Oncogene Mouse/human; 115 




LAMC2 FAK CASC9 by targeting LAMC2 
could promote migration, 
invasion, and metastasis in 
ESCC via FAK/PI3K/Akt 
signaling pathway. 
[212] 
Bladder Cancer (BCa) HULC Oncogene Mouse/human; 276 
pairs of BCa and ANCTs 
T24, RT4 ZIC2 _ HULC by targeting ZIC2 could 
promote BCa cell proliferation 
and inhibit apoptosis. 
[213]  
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Table 6 
Diagnostic/ prognostic role of PI3K/AKT-associated lncRNAs in human cancers.  
Samples Area Under 
Curve 
Sensitivity Specificity Kaplan-Meier Analysis Univariate Cox 
Regression 
Multivariate Cox Regression Ref 
108 AML 
patients 
_ _ _ High amounts of HOXA-AS2 
were associated with shorter OS 
and RFS. 
_ High expression of HOXA-AS2 was 
correlated with MRD positivity. 
[147] 
88 NPC patients _ _ _ High amounts of HAGLROS 
were associated with shorter OS 
rate. 
_ _ [153] 
92 glioma 
patients 
_ _ _ High amounts of BCAR4 were 
associated with shorter OS rate. 
_ High expression of BCAR4 was 
correlated with advanced WHO grade. 
[148] 
42 RCC patients _ _ _ Up-regulation of HOTTIP was 
associated with a shorter OS 
rate. 
- _ [199] 
64 GC patients _ _ _ High expression of MALAT1 was 
associated with a shorter OS 
rate. 
_ _ [202] 
56 GC patients 0.7699 
(SLC25A5- 
AS1) 
_ _ _ _ _ [133] 
76 HCC patients _ _ _ Up-regulation of CASC11 was 
associated with a shorter OS 
rate. 
_ _ [149] 
82 PTC patients _ _ _ Up-regulation of ABHD11-AS1 
was associated with a shorter OS 
rate. 
_ _ [181] 
80 CRC patients 0.922 97.5 80.0 Up-regulation of TINCR was 
associated with a shorter OS 
rate. 
_ High expression of TINCR was 
correlated with tumor differentiation 
and TNM stage. 
[203] 
119 OS patients _ _ _ Up-regulation of DBH-AS1 was 
associated with a shorter OS 
rate. 
_ High expression of DBH-AS1 was 
correlated with advanced lymph node 
status and metastasis status. 
[189] 
72 TSCC patients 0.9514 _ _ High expression of MALAT1 was 
associated with a shorter OS 
rate. 
_ _ [208] 
57 OS patients _ _ _ High expression of ANRIL was 
associated with a shorter OS 
rate. 
_ _ [190] 
102 SACC 
patients 
_ _ _ High expression of ADAMTS9- 
AS2 was associated with a 
shorter OS rate. 
_ _ [210] 
23 HCC patients _ _ _ Up-regulation of CRNDE was 
associated with shorter OS and 
DFS rates. 
_ _ [174] 
36 CRC patients _ _ _ Up-regulation of LINC01296 
was associated with a shorter OS 
rate. 
_ _ [206] 
40 ccRCC 
patients 
_ _ _ High expression of TP73-AS1 
was associated with shorter OS 
and DFS rates. 
_ _ [198] 
77 TC patients 0.7360 _ _ High expression of XIST was 
associated with a shorter OS 
rate. 
High expression of XIST 





_ _ _ High expression of CASC9 was 
associated with a shorter OS 
rate. 
_ _ [212] 
39 BCa patients _ _ _ Low expression of 
LINC00641was associated with 
shorter OS and PFS rates. 
_ _ [139] 
53 CRC patients _ _ _ High expression of SNHG7 was 
associated with shorter OS and 
DFS rates. 
_ High expression of SNHG7 was 
correlated with lymphatic metastasis, 






_ _ _ High expression of CDKN2B- 
AS1 was associated with a 
shorter OS rate. 
_ _ [172] 
136 HCC 
patients 
_ _ _ High expression of PTTG3P was 
associated with a shorter OS 
rate. 
High expression of 
PTTG3P was correlated 
with tumor size. 
High expression of PTTG3P was 
correlated with advanced TNM stage. 
[173] 
68 OS patients _ _ _ High expression of MALAT1 was 
associated with shorter OS and 
DFS rates. 
_ High expression of MALAT1 was 
correlated with tumor size and 
metastasis. 
[192] 
71 GC patients _ _ _ Low expression of ADAMTS9- 
AS2 was associated with a 
shorter OS rate. 
_ _ [125] 
77 CRC patients _ _ _ _ _ [207] 
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